(Total Views: 694)
Posted On: 09/12/2019 7:27:54 PM
Post# of 85917
I'm sure Dr. D would be aware of a number of them due to his industry and personal contacts, but there are just so many out there - and quite a few will be able to fly under the radar due to being closely held / non-public entities or CDMO's simply contracted by 'anonymous' third parties under strict NDA's. Also, for limited liability and commercial viability reasons, many CDMO's are purposely small and super discrete.
Cardiol Therapeutics is working with Dalton Pharma (not affiliated with Dr.D) and Noramco to develop cannabinoid heart failure drugs. Ginko Bioworks, a Bayer provider, are working with Cronos to develop medicinal cannabinoids. Sandoz / Novartis are working with Tilray to do the same. Sanofi working with Opiant - developer of Narcan. Aurora Cannabis and Farmacias, MedMen and PharmaCann, Scythian Biosciences and Aphria etc etc etc. Abbvie already have Marionol and are developing other cannabinoid treatments. Zynerba have two cannabinoid therapies in development (coincidentally with transdermal patch delivery). Insys Therapeutics are developing sublingual cannabinoid pain meds. Corbus is working on cannabinoid based cystic fibrosis treatments. Seriously, this is just a tiny sample - as of June 2018 there were over 100 cannabinoid-based clinical trials underway and registered with the FDA, a year on - who knows?
Looking at the cannabis/cannabinoid patents in North America it's pretty evident Big Pharma have not been sitting back waiting - Abbvie have 59 patents, Sanofi 39, Merck 35, Myers-Squibb 34, GW 28, Pfizer 25, Novartis 21, Roche 17. For good measure and as a comparison, Hebrew University of Jerusalem have 19.
UNVC may well have some affiliation or agreements in place with a number of these, but it does give some indication of the future direction of the pharmaceutical CBD/THC market - THE BIG BOYS WANT IN - and I just hope and pray Univec and the good Dr. D get there first.
Apologies for the lengthy post.
Cardiol Therapeutics is working with Dalton Pharma (not affiliated with Dr.D) and Noramco to develop cannabinoid heart failure drugs. Ginko Bioworks, a Bayer provider, are working with Cronos to develop medicinal cannabinoids. Sandoz / Novartis are working with Tilray to do the same. Sanofi working with Opiant - developer of Narcan. Aurora Cannabis and Farmacias, MedMen and PharmaCann, Scythian Biosciences and Aphria etc etc etc. Abbvie already have Marionol and are developing other cannabinoid treatments. Zynerba have two cannabinoid therapies in development (coincidentally with transdermal patch delivery). Insys Therapeutics are developing sublingual cannabinoid pain meds. Corbus is working on cannabinoid based cystic fibrosis treatments. Seriously, this is just a tiny sample - as of June 2018 there were over 100 cannabinoid-based clinical trials underway and registered with the FDA, a year on - who knows?
Looking at the cannabis/cannabinoid patents in North America it's pretty evident Big Pharma have not been sitting back waiting - Abbvie have 59 patents, Sanofi 39, Merck 35, Myers-Squibb 34, GW 28, Pfizer 25, Novartis 21, Roche 17. For good measure and as a comparison, Hebrew University of Jerusalem have 19.
UNVC may well have some affiliation or agreements in place with a number of these, but it does give some indication of the future direction of the pharmaceutical CBD/THC market - THE BIG BOYS WANT IN - and I just hope and pray Univec and the good Dr. D get there first.
Apologies for the lengthy post.
(8)
(0)Scroll down for more posts ▼
